

Estimate change	
TP change	
Rating change	

**CMP: INR2,073      TP: INR2,200 (+7%)      Neutral**

## Niche products and superior execution lead to robust 4Q and FY25 performance

Bloomberg	LPC IN
Equity Shares (m)	457
M.Cap.(INRb)/(USD\$b)	946.5 / 11.1
52-Week Range (INR)	2403 / 1493
1, 6, 12 Rel. Per (%)	-4/-4/14
12M Avg Val (INR M)	2418

### Steady progress, but upside capped

- Lupin (LPC) delivered slightly better-than-expected revenue, EBITDA, and PAT for the quarter (4% beat).
- LPC continues to track well in the US generics segment (40% of 4Q sales), clocking the highest quarterly run-rate of USD245m over the past 24 quarters.
- The strong 47% YoY earnings growth for 4QFY25 was supported by healthy growth in key geographies, a higher share of limited competition products, PLI income, and a lower tax rate.
- The superior product mix has led LPC to achieve a peak gross margin of 70% in 36 quarters.
- Outperformance to the industry in certain therapies, such as diabetes, cardiology, and gastrointestinal in the domestic formulation (DF; 30% of 4Q sales) segment, is offset by subdued performance in the in-licensed portfolio and a weak show in the anti-infectives segment.
- LPC delivered strong execution in other developed markets (up 30% YoY) as well, by expanding its offerings and its reach.
- We raise our earnings estimates by 8%/7% for FY26/FY27, factoring in 1) launches in inhalation/injectables/biosimilars segments in the US/EU and other developed markets, 2) better-than-industry growth aided by rising chronic therapies' share in the DF segment, and 3) increased R&D spending towards building a complex product pipeline. We value LPC at 25x 12M forward earnings to arrive at our TP of INR2,220.
- While LPC has delivered phenomenal financial performance over the past three years (adj. PAT surged from a low of INR4b in FY23 to INR33b in FY25), we expect 12% earnings CAGR over FY25-27, as new launch benefits would be offset to some extent by higher competition in the base business. **We reiterate our Neutral rating.**

### Financials & Valuations (INR b)

Y/E MARCH	FY25	FY26E	FY27E
Sales	225.0	252.1	277.9
EBITDA	52.7	60.4	64.9
Adj. PAT	32.7	38.3	41.1
EBIT Margin (%)	18.2	19.4	19.1
Cons. Adj. EPS (INR)	71.6	84.2	90.3
EPS Gr. (%)	72.4	17.1	7.3
BV/Sh. (INR)	376.8	460.0	550.8

### Ratios

Net D:E	0.1	-0.1	-0.2
RoE (%)	20.8	20.1	17.9
RoCE (%)	17.7	16.9	15.7
Payout (%)	4.1	3.5	0.0

### Valuations

P/E (x)	28.9	24.6	22.9
EV/EBITDA (x)	18.3	15.3	13.7
Div. Yield (%)	0.1	0.1	0.0
FCF Yield (%)	0.2	4.1	4.2
EV/Sales (x)	4.3	3.7	3.2

### Shareholding pattern (%)

As On	Mar-25	Dec-24	Mar-24
Promoter	46.9	47.0	47.0
DII	25.4	24.8	27.8
FII	21.5	22.0	18.3
Others	6.2	6.3	6.9

FII Includes depository receipts

### Broad-based growth and margin expansion lift PAT (up 47% YoY)

- LPC expects the EBITDA margin to be 23-23.5% for FY25. LPC delivered a 9MFY25 EBITDA margin of 24%.
- Lupin's (LPC) 4QFY25 revenue grew 14.2% YoY to INR56.7b (our est. INR54.7b). The US sales rose 19% YoY to INR22.6b (up 17% YoY in CC to USD245m; 41% of sales). Domestic formulation (DF) sales grew 6.9% YoY to INR17.1b (31% of sales). Other developed market sales increased 30.9% YoY to INR6.9b (12% of sales). Emerging market sales rose 10.4% YoY to INR 6.7b (12% of sales), while API sales dipped 10.3% YoY to INR2.3b (4% of sales).
- Gross margin (GM) expanded 200bp YoY to 70.2% due to better product mix.
- EBITDA margin expanded 270bp YoY to 22.8%, largely fueled by better GM and aided by reduced other expenses (-110bp YoY as a % of sales).
- As a result, EBITDA grew 29.6% YoY to INR12.9b (vs. our est: INR12.4b).
- Adj. PAT grew 47% YoY INR7.5b (vs. our est: INR7.45b).
- For FY25, its revenue/EBITDA/PAT grew 14%/47%/73% YoY to INR225b/ INR52.7b/INR32.7b.

### Highlights from the management commentary

- LPC expects the EBITDA margin to be 23-23.5% for FY25. LPC delivered a 9MFY25 EBITDA margin of 24%.
- LPC expects a double-digit YoY growth in the US business vs. earlier guidance of a single-digit YoY growth for FY25.
- LPC projected USD1b in US sales for FY26E, assuming competition for Mirabegron and Albuterol, while incremental revenue is likely from Tolvaptan in 1HFY26 and injectables in 2HFY26.
- R&D spending will be INR18b for FY25, implying R&D to be higher for 4QFY25. Five complex generic nasal sprays are expected to be filed in 4Q.
- LPC filed Ranibizumab for the EU market.

### Quarterly Performance (Consolidated)


Y/E March	FY24				FY25				FY24	FY25E	FY25E	% Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
<b>Net Sales</b>	<b>46,087</b>	<b>50,385</b>	<b>51,974</b>	<b>49,608</b>	<b>56,003</b>	<b>55,427</b>	<b>56,927</b>	<b>56,671</b>	<b>1,98,054</b>	<b>2,25,028</b>	<b>54,671</b>	<b>3.7</b>
YoY Change (%)	23.1	21.5	20.2	12.0	21.5	10.0	9.5	14.2	19.0	13.6	10.2	
Total Expenditure	39,574	41,153	41,755	39,640	42,389	43,059	43,162	43,750	1,62,123	1,72,361	42,229	
<b>EBITDA</b>	<b>6,513</b>	<b>9,232</b>	<b>10,220</b>	<b>9,968</b>	<b>13,614</b>	<b>12,368</b>	<b>13,765</b>	<b>12,921</b>	<b>35,932</b>	<b>52,668</b>	<b>12,442</b>	<b>3.9</b>
YoY Change (%)	297.3	112.6	83.8	65.0	109.0	34.0	34.7	29.6	104.4	46.6	24.8	
Margins (%)	14.1	18.3	19.7	20.1	24.3	22.3	24.2	22.8	18.1	23.4	22.8	
Depreciation	2,347	2,479	2,572	2,559	2,477	2,569	2,715	3,932	9,956	11,693	2,495	
<b>EBIT</b>	<b>4,166</b>	<b>6,754</b>	<b>7,648</b>	<b>7,409</b>	<b>11,137</b>	<b>9,799</b>	<b>11,050</b>	<b>8,989</b>	<b>25,977</b>	<b>40,975</b>	<b>9,947</b>	<b>-9.6</b>
YoY Change (%)		192.7	127.9	117.9	167.3	45.1	44.5	21.3	196.0	57.7	34.3	
Margins (%)	9.0	13.4	14.7	14.9	19.9	17.7	19.4	15.9	13.1	18.2	18.2	
Interest	856	806	740	713	680	709	669	891	3,116	2,949	711	
Other Income	228	404	294	293	678	423	537	570	1,218	2,207	462	
EO Exp/(Inc)	-2,053	54	-160	2,012	1,204	-1,036	956	-291	-147	834	0	
<b>PBT</b>	<b>5,591</b>	<b>6,298</b>	<b>7,361</b>	<b>4,977</b>	<b>9,930</b>	<b>10,549</b>	<b>9,963</b>	<b>8,958</b>	<b>24,227</b>	<b>39,401</b>	<b>9,698</b>	<b>-7.6</b>
Tax	1,055	1,344	1,174	1,295	1,875	1,954	2,124	1,135	4,867	7,087	2,300	
Rate (%)	18.9	21.3	15.9	26.0	18.9	18.5	21.3	12.7	20.1	18.0	23.7	
Minority Interest	-11	-57	-56	-88	-42	-69	-37	-99	-211	-246	51	
<b>Reported PAT</b>	<b>4,525</b>	<b>4,898</b>	<b>6,131</b>	<b>3,594</b>	<b>8,013</b>	<b>8,526</b>	<b>7,802</b>	<b>7,726</b>	<b>19,149</b>	<b>32,067</b>	<b>7,450</b>	<b>3.7</b>
<b>Adj PAT</b>	<b>2,855</b>	<b>4,940</b>	<b>5,997</b>	<b>5,083</b>	<b>8,990</b>	<b>7,682</b>	<b>8,554</b>	<b>7,472</b>	<b>18,875</b>	<b>32,698</b>	<b>7,450</b>	<b>0.3</b>
YoY Change (%)	LP	319.9	256.1	95.0	214.9	55.5	42.6	47.0	382.1	73.2	46.6	
Margins (%)	6.2	9.8	11.5	10.2	16.1	13.9	15.0	13.2	9.5	14.5	13.6	
<b>EPS</b>	<b>6</b>	<b>11</b>	<b>13</b>	<b>11</b>	<b>20</b>	<b>17</b>	<b>19</b>	<b>16</b>	<b>42</b>	<b>72</b>	<b>16</b>	<b>0.3</b>

### Key performance Indicators (Consolidated)

Y/E March	FY24				FY25				FY24	FY25	FY25
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			
<b>INRm</b>											
Domestic formulations	16,384	16,915	17,251	16,015	19,259	20,096	19,305	17,113	66,564	75,773	17,889
YoY Change (%)	9.8	6.8	13.4	8.3	17.5	18.8	11.9	6.9	9.6	13.8	11.7
US formulations	15,905	18,666	18,885	19,006	20,408	19,711	21,213	22,618	72,462	83,950	21,514
YoY Change (%)	57.4	40.4	23.7	22.6	28.3	5.6	12.3	19.0	33.8	15.9	13.2
Other developed markets	3987	4759	5170	5318	5031	5693	6249	6915	19235	23888	5724.3
YoY Change (%)	19.6	23.9	36.0	17.3	26.2	19.6	20.9	30.0	24.0	18.0	7.6
Emerging markets	5721	6368	6714	6031	6823	6525	6528	6660	24834	26536	4441.6
YoY Change (%)	11.5	17.2	25.6	14.8	19.3	2.5	(2.8)	10.4	17.3	6.9	(12.8)
API	3,371	2,684	2,779	2,581	3,622	2,944	2,891	2,316	11,415	11,773	2,757
YoY Change (%)	32.1	7.4	(1.3)	(20.0)	7.4	9.7	4.0	(10.3)	2.9	7.0	6.8
<b>Cost Break-up</b>											
RM Cost (% of Sales)	35.6	33.8	33.2	31.7	31.2	30.5	30.2	29.8	34.2	30.8	30.1
Staff Cost (% of Sales)	18.3	17.1	17.1	18.1	17.3	18.2	17.3	17.7	18.0	17.9	17.6
R&D Expenses(% of Sales)	8.0	7.5	6.9	8.6	6.2	8.1	7.6	9.4	7.8	8.0	8.9
Other Cost (% of Sales)	24.0	23.3	23.2	21.5	21.0	20.9	20.7	20.3	23.4	21.0	20.7
Gross Margins(%)	64.4	66.2	66.8	68.3	68.8	69.5	69.8	70.2	65.8	69.2	69.9
EBITDA Margins(%)	14.1	18.3	19.7	20.1	24.3	22.3	24.2	22.8	18.1	23.4	22.8
EBIT Margins(%)	9.0	13.4	14.7	14.9	19.9	17.7	19.4	15.9	13.1	18.2	18.2


## Key exhibits

**Exhibit 1: US sales increased 19% YoY in 4QFY25**



Source: MOFSL, Company

**Exhibit 2: DF sales up 6.9% YoY in 4QFY25**



Source: MOFSL, Company

## A short phase of steady growth after two high-growth years

### US – progress underway to strengthen the complex generics pipeline

- In FY25, the US sales grew 16% YoY to INR84b (USD925m; up 13.4% in CC terms), supported by limited competition product launches like g-spiriva, Pred Forte Gx, and Mirabegron. Accordingly, from the low of USD632m, LPC achieved annual sales of USD925m in FY25.
- LPC has a target of 100 new launches, with 65% of new launches from the complex generic category by FY30.
- LPC's R&D effort towards product development is expected to increase the share of complex generics by 49% in FY30 from 31% in FY25.
- The complex generics are going to be injectables, inhalations, biosimilars, and other value-added medicines.
- While new approvals are expected to drive US generics sales, the competition in the base portfolio might keep growth in US generics in check. We expect 8% sales CAGR in the US over FY25-27 to USD1.1b.


### DF – Efforts ongoing to enhance differentiated offerings and increase the overall chronic share

- In FY25, DF sales grew at a robust rate of 14% YoY to INR75b due to industry outperformance in therapies like diabetes/cardiology and GI.
- The subdued growth in the anti-infectives segment affected the overall performance to some extent.
- With an MR strength of 10,400 and a focus on innovation pipeline, LPC is implementing the effort to increase the share of the chronic segment, thereby aiding consistent growth prospects in the DF segment going forward.
- Further, focus on GLP-1 and expansion in therapies such as GI, onco, CNS, and VMS are likely to sustain better-than-industry growth in the DF segment.
- We expect an 11% sales CAGR in this segment to reach INR94b over FY25-27.

**Maintain Neutral**


- We raise our earnings estimates by 8%/7% for FY26/FY27, factoring in 1) launches in inhalation/injectables/biosimilars segments in the US/EU and other developed markets, 2) better-than-industry growth aided by rising chronic therapies' share in the DF segment, and 3) increased R&D spending towards building a complex product pipeline. We value LPC at 25x 12M forward earnings to arrive at our TP of INR2,220.
- While LPC has delivered phenomenal financial performance over the past three years (adj. PAT surged from a low of INR4b in FY23 to INR33b in FY25), we expect 12% earnings CAGR over FY25-27, as new launch benefits would be offset to some extent by higher competition in the base business. **We reiterate our Neutral rating.**

**Exhibit 3: P/E chart**




## Story in charts


**Exhibit 4: Revenue mix in 4QFY25**




**Exhibit 5: Expect 11% sales CAGR over FY25-27**




**Exhibit 6: R&D spending to inch up going forward**




**Exhibit 7: EBITDA margin to be stable over FY25-27**



**Exhibit 8: Expect EPS to register 12% CAGR over FY25-27**



**Exhibit 9: 101 ANDAs – pending approval**



Source: MOFSL, Company,

## Financials and valuations

Income Statement									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>Net Sales</b>	<b>1,46,646</b>	<b>1,53,748</b>	<b>1,50,930</b>	<b>1,60,321</b>	<b>1,66,417</b>	<b>1,98,054</b>	<b>2,25,028</b>	<b>2,52,134</b>	<b>2,77,861</b>
Change (%)	-7.2	4.8	-1.8	6.2	3.8	19.0	13.6	12.0	10.2
<b>EBITDA</b>	<b>25,607</b>	<b>23,548</b>	<b>25,316</b>	<b>19,968</b>	<b>17,582</b>	<b>35,932</b>	<b>52,668</b>	<b>60,436</b>	<b>64,875</b>
Margin (%)	17.5	15.3	16.8	12.5	10.6	18.1	23.4	24.0	23.3
Depreciation	8,461	9,702	8,874	8,220	8,807	9,956	11,693	11,428	11,910
<b>EBIT</b>	<b>17,147</b>	<b>13,846</b>	<b>16,442</b>	<b>11,748</b>	<b>8,775</b>	<b>25,977</b>	<b>40,975</b>	<b>49,009</b>	<b>52,965</b>
Int. and Finance Charges	3,025	3,630	1,406	1,428	2,743	3,116	2,949	3,367	3,043
Other Income - Rec.	3,330	3,578	1,479	1,504	757	1,218	2,207	2,350	2,550
<b>PBT before EO item</b>	<b>17,452</b>	<b>13,794</b>	<b>16,515</b>	<b>11,824</b>	<b>6,790</b>	<b>24,079</b>	<b>40,234</b>	<b>47,992</b>	<b>52,472</b>
EO Expense/(Income)	3,400	6,261	-236	25,550	-375	-147	834	0	0
<b>PBT after EO item</b>	<b>14,052</b>	<b>7,533</b>	<b>16,751</b>	<b>-13,726</b>	<b>7,165</b>	<b>24,227</b>	<b>39,400</b>	<b>47,992</b>	<b>52,472</b>
Tax	8,879	11,571	4,485	1,372	2,688	4,867	7,087	9,618	11,322
Tax Rate (%)	63.2	153.6	26.8	-10.0	37.5	20.1	18.0	20.0	21.6
Less: Minority Interest	52	-43	-101	-183	-176	-211	-246	-97	-97
<b>Reported PAT</b>	<b>5,121</b>	<b>-3,995</b>	<b>12,165</b>	<b>-15,280</b>	<b>4,301</b>	<b>19,149</b>	<b>32,066</b>	<b>38,277</b>	<b>41,053</b>
<b>PAT Adj for EO items</b>	<b>6,066</b>	<b>10,572</b>	<b>11,790</b>	<b>8,699</b>	<b>3,915</b>	<b>18,875</b>	<b>32,698</b>	<b>38,277</b>	<b>41,053</b>
Change (%)	-58.0	74.3	11.5	-26.2	-55.0	382.1	73.2	17.1	7.3
Margin (%)	4.1	6.9	7.8	5.4	2.4	9.5	14.5	15.2	14.8

Consolidated Balance Sheet									(INR m)
Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
Equity Share Capital	905	906	907	909	910	909	913	909	909
Total Reserves	1,36,517	1,24,461	1,37,124	1,20,624	1,23,695	1,41,992	1,71,122	2,15,562	2,56,802
<b>Net Worth</b>	<b>1,37,422</b>	<b>1,25,367</b>	<b>1,38,031</b>	<b>1,21,533</b>	<b>1,24,605</b>	<b>1,42,901</b>	<b>1,72,035</b>	<b>2,16,471</b>	<b>2,57,711</b>
Minority Interest	469	445	550	687	783	831	909	1,006	1,103
Deferred liabilities	-4,457	252	496	711	738	-567	-6,053	-3,327	-3,327
Secured Loan	70,546	25,180	6,133	6,147	4,153	3,115	20,820	20,570	20,320
Unsecured Loan	15,802	24,928	30,494	37,023	42,165	26,699	34,173	29,104	25,104
Total Loans	86,347	50,108	36,627	43,170	46,318	29,814	54,993	49,675	45,425
<b>Capital Employed</b>	<b>2,19,781</b>	<b>1,76,172</b>	<b>1,75,704</b>	<b>1,66,101</b>	<b>1,72,444</b>	<b>1,72,979</b>	<b>2,21,884</b>	<b>2,63,824</b>	<b>3,00,912</b>
Gross Block	72,189	76,431	85,479	95,368	1,05,127	1,17,618	1,31,807	1,37,084	1,43,147
Less: Accum. Deprn.	23,073	32,776	41,650	49,870	58,677	68,632	80,325	91,753	1,03,662
<b>Net Fixed Assets</b>	<b>49,115</b>	<b>43,656</b>	<b>43,829</b>	<b>45,498</b>	<b>46,450</b>	<b>48,986</b>	<b>51,482</b>	<b>45,331</b>	<b>39,485</b>
Capital WIP	10,186	7,582	8,515	8,475	8,948	5,957	3,555	5,127	5,914
Investments	22,954	23,743	24,549	9,000	5,169	10,747	13,840	13,840	13,840
Goodwill & Intangibles	67,963	37,540	37,126	31,306	40,534	41,566	47,323	47,323	47,323
<b>Curr. Assets</b>	<b>1,21,935</b>	<b>1,35,575</b>	<b>1,20,283</b>	<b>1,22,236</b>	<b>1,26,861</b>	<b>1,29,656</b>	<b>1,69,796</b>	<b>2,20,575</b>	<b>2,70,680</b>
Inventory	38,368	34,569	40,920	46,307	44,918	49,539	54,764	58,220	67,391
Account Receivables	51,498	54,459	44,743	42,619	44,807	46,920	54,971	63,501	72,225
Cash and Bank Balance	9,872	24,543	17,425	10,981	12,931	12,025	31,423	70,168	1,02,378
Others	22,197	22,004	17,195	22,328	24,205	21,171	28,638	28,686	28,686
<b>Curr. Liability &amp; Prov.</b>	<b>52,372</b>	<b>71,924</b>	<b>58,598</b>	<b>50,414</b>	<b>55,519</b>	<b>63,931</b>	<b>64,111</b>	<b>68,372</b>	<b>76,329</b>
Account Payables	41,390	59,884	47,460	42,254	46,937	54,928	57,019	61,280	69,236
Provisions	10,982	12,040	11,139	8,160	8,581	9,003	7,093	7,093	7,093
<b>Net Current Assets</b>	<b>69,563</b>	<b>63,651</b>	<b>61,685</b>	<b>71,822</b>	<b>71,342</b>	<b>65,725</b>	<b>1,05,685</b>	<b>1,52,203</b>	<b>1,94,351</b>
<b>Appl. of Funds</b>	<b>2,19,781</b>	<b>1,76,172</b>	<b>1,75,704</b>	<b>1,66,101</b>	<b>1,72,444</b>	<b>1,72,979</b>	<b>2,21,884</b>	<b>2,63,823</b>	<b>3,00,911</b>

## Financials and valuations

### Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
<b>EPS (Fully Diluted)</b>	<b>13.4</b>	<b>23.3</b>	<b>26.0</b>	<b>19.1</b>	<b>8.6</b>	<b>41.5</b>	<b>71.6</b>	<b>84.2</b>	<b>90.3</b>
Cash EPS (Fully Diluted)	32.1	44.8	45.5	37.2	28.0	63.4	97.2	109.4	116.5
BV/Share	303.7	276.7	304.2	267.4	273.9	314.4	376.8	476.3	567.0
DPS	5.0	9.0	7.0	9.0	2.0	2.5	2.5	2.5	0.0
Payout (%)	53.3	-119.0	30.4	-31.3	24.7	6.9	4.1	3.5	0.0
<b>Valuation (x)</b>									
P/E (Fully Diluted)	154.4	88.8	79.7	108.2	240.6	49.8	28.9	24.6	22.9
Cash P/E (Fully Diluted)	64.5	46.3	45.4	55.6	74.0	32.6	21.3	18.9	17.8
P/BV	6.8	7.5	6.8	7.7	7.6	6.6	5.5	4.3	3.7
EV/Sales	6.9	6.3	6.4	6.1	5.9	4.8	4.3	3.7	3.2
EV/EBITDA	39.7	41.0	37.9	48.7	55.4	26.7	18.3	15.2	13.6
<b>Return Ratios (%)</b>									
RoE	4.4	8.0	9.0	6.7	3.2	14.1	20.8	19.7	17.3
RoCE	3.5	4.8	7.5	8.6	3.5	12.6	17.7	16.7	15.3
RoIC	3.6	5.1	9.8	9.8	3.9	14.3	21.2	22.5	23.5
<b>Working Capital Ratios</b>									
Asset Turnover (x)	0.7	0.9	0.9	1.0	1.0	1.1	1.0	1.0	0.9
Fixed Asset Turnover (x)	3.0	3.3	3.5	3.6	3.6	4.2	4.5	5.2	6.6
Debtor (Days)	128	129	108	97	98	86	89	92	95
Creditor (Days)	184	162	137	129	136	163	158	156	159
Inventory (Days)	95	82	99	105	99	91	89	84	89
<b>Leverage Ratio</b>									
Current Ratio	2.3	1.9	2.1	2.4	2.3	2.0	2.6	3.2	3.5
Interest Cover Ratio	5.7	3.8	11.7	8.2	3.2	8.3	13.9	14.6	17.4
Debt/Equity (x)	0.6	0.2	0.1	0.3	0.3	0.1	0.1	-0.1	-0.2

### Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E
PBT Before Extraordinary items	15,172	8,768	16,765	-13,722	7,165	24,223	40,150	60,436	64,875
Interest/Dividends Recd.	2,037	2,194	808	468	2,422	2,280	1,589	2,350	2,550
Direct Taxes Paid	-9,394	-5,112	-6,954	469	-2,432	-3,261	-9,060	-6,892	-11,322
(Inc)/Dec in WC	-5,002	-4,710	-1,925	-150	3,265	855	-14,105	-7,773	-9,937
<b>CF from Operations</b>	<b>2,812</b>	<b>1,139</b>	<b>8,694</b>	<b>-12,936</b>	<b>10,420</b>	<b>24,098</b>	<b>18,573</b>	<b>48,121</b>	<b>46,166</b>
Others	13,847	13,549	9,524	16,609	8,552	12,386	11,426	2	2
<b>CF from Op. incl EO Exp.</b>	<b>16,660</b>	<b>14,688</b>	<b>18,218</b>	<b>3,673</b>	<b>18,972</b>	<b>36,484</b>	<b>29,999</b>	<b>48,123</b>	<b>46,168</b>
(inc)/dec in FA	-9,599	-6,713	-6,714	-8,980	-14,611	-9,166	-16,531	-6,850	-6,850
<b>Free Cash Flow</b>	<b>-6,786</b>	<b>-5,574</b>	<b>1,980</b>	<b>-21,916</b>	<b>-4,191</b>	<b>14,931</b>	<b>2,042</b>	<b>41,271</b>	<b>39,316</b>
(Pur)/Sale of Investments	-20,245	-1,192	-255	15,891	3,958	-5,374	-324	0	0
Others	-2,981	18,974	-5,427	6,011	-2,214	-2,582	-24,864	0	0
<b>CF from Investments</b>	<b>-32,825</b>	<b>11,070</b>	<b>-12,396</b>	<b>12,922</b>	<b>-12,868</b>	<b>-17,122</b>	<b>-41,719</b>	<b>-6,850</b>	<b>-6,850</b>
Change in Net Worth	37	60	108	161	19	146	399	7,486	185
Inc/(Dec) in Debt	12,922	-2,674	-14,719	-11,693	700	-17,331	24,277	-5,319	-4,250
Interest Paid	-2,804	-3,562	-1,518	-1,240	-2,267	-2,829	-2,295	-3,367	-3,043
Dividend Paid	-2,248	-2,265	-2,723	-2,951	-1,825	-1,828	-3,653	-1,329	0
<b>CF from Fin. Activity</b>	<b>7,441</b>	<b>-8,906</b>	<b>-18,853</b>	<b>-15,723</b>	<b>-3,373</b>	<b>-21,842</b>	<b>17,319</b>	<b>-2,528</b>	<b>-7,107</b>
<b>Inc/Dec of Cash</b>	<b>-8,724</b>	<b>16,853</b>	<b>-13,031</b>	<b>872</b>	<b>2,732</b>	<b>-2,481</b>	<b>5,599</b>	<b>38,745</b>	<b>32,210</b>
Add: Beginning Balance	14,164	5,441	22,293	9,262	9,913	12,317	9,836	15,436	54,180
Cash/Cash Eq. at end of the year	5,441	22,293	9,262	10,134	12,645	9,836	15,436	54,180	86,390
Forex/Bank	0	0	0	-221	-328	0	15,988	15,988	15,988
<b>Closing Balance</b>	<b>5,441</b>	<b>22,293</b>	<b>9,262</b>	<b>9,913</b>	<b>12,317</b>	<b>9,836</b>	<b>31,423</b>	<b>70,168</b>	<b>1,02,378</b>

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

## NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

**Disclosures**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

**Regional Disclosures (outside India)**

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

**For Hong Kong:**

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

**For U.S.**

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

**For Singapore**

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com).

Nainesh Rajani

Email: [nainesh.rajani@motilaloswal.com](mailto:nainesh.rajani@motilaloswal.com)

Contact: (+65) 8328 0276

**Specific Disclosures**

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).  
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.  
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.  
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.  
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.  
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

\*\*\*\*\*  
The associates of MOFSL may have:  
financial interest in the subject company  
actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months  
any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months  
be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Mital Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

#### Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.